Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$73.17

-0.73 (-0.99%)

16:52
08/09/17
08/09
16:52
08/09/17
16:52

Galapagos: halts disease progression in IPF patients in FLORA Phase 2a trial

Galapagos announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis in the FLORA Phase 2a trial. FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received GLPG1690 and 6 placebo. Primary objectives of the trial were to assess safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG1690 in an IPF patient population. Secondary objectives included the evaluation of lung function, changes in disease biomarkers, FRI, and quality of life. The IPF diagnosis was confirmed by central reading. The baseline characteristics of the recruited population were in line with published data in similarly conducted studies and were balanced between active and placebo. Patients with previous experience on nintedanib or pirfenidone were required to have discontinued treatment with either agent for at least 4 weeks prior to initiating treatment with GLPG1690. Over the 12-week period, patients receiving GLPG1690 showed an FVC increase of 8 mL, while patients on placebo showed an FVC reduction of 87 mL (mean from baseline). Such reductions in FVC in the placebo arm were in line with expectations based on similarly conducted third-party studies in IPF patients. In addition to the demonstrated absence of lung function decline over the 12 week period, more sensitive functional respiratory imaging (FRI) confirmed disease stabilization in the GLPG1690 arm, versus disease progression in the placebo arm, reaching statistical significance on two specific parameters. Patients on GLPG1690 treatment showed a clear reduction of serum LPA18:2, a biomarker for autotaxin inhibition, as expected based on the mechanism of action of GLPG1690. Thus, the level of target engagement observed in Phase 1 with healthy volunteers was confirmed in IPF patients in FLORA. GLPG1690 was found to be generally well tolerated in this Phase 2 trial. Rates of discontinuation due to adverse events, as well as serious adverse event rates, were similar between patients on GLPG1690 and placebo. Galapagos plans to rapidly progress GLPG1690 in a late stage trial and had already discussions with regulators regarding trial design.

  • 10

    Aug

GLPG Galapagos NV
$73.17

-0.73 (-0.99%)

06/22/17
NOMU
06/22/17
NO CHANGE
Target $108
NOMU
Buy
Galapagos NV price target lowered to $108 from $121 at Nomura Instinet
Nomura Instinet analyst Christopher Marai lowered Glapagos' price target to $108 from $121 given the delay in the triple-combo study of its cystic fibrosis program. The analyst is now forecasting commercialization of the triple combo in 2022, versus 2021 previously, saying he continues to view the figotinib program is largely de-risked and maintains a Buy rating.
06/22/17
NOMU
06/22/17
NO CHANGE
Target $108
NOMU
Buy
Galapagos NV price target lowered to $108 from $121 at Nomura Instinet
Nomura Instinet analyst Christopher Marai noted that Galapagos revealed during an R&D day that it has pushed back the initiation of its cystic fibrosis triple-combo study to year end from mid-2017, which he believes will delay commercialization of the triple combo to 2022 from his prior 2021 forecast. Given the anticipated delay, he lowered his price target on Galapagos to $108 from $121, though he keeps a Buy rating as he feels CF program readouts may drive near-term upside.
04/24/17
04/24/17
DOWNGRADE
Target $73

Sell
Janney says Galapagos NV 'priced to perfection,' cuts two notches to Sell
As previously reported, Janney Capital analyst Debjit Chattopadhyay downgraded Galapagos NV (GLPG) to Sell from Neutral, stating that while the baricitinib setback suffered by competitors Incyte (INCY) and Eli Lilly (LLY) was "obviously great news," filgotinib is still more than 2 years from commercialization and over seven years away from peak sales. The majority of the positives are already reflected in the stock, even "generously" assuming peak sales for filgotinib above $3B, said Chattopadhyay, who has a $73 fair value estimate on Galapagos shares, which closed Friday at $85.84.
04/24/17
JANY
04/24/17
DOWNGRADE
JANY
Sell
Galapagos NV downgraded to Sell from Buy at Janney Capital

TODAY'S FREE FLY STORIES

SPN

Superior Energy

$8.81

-0.14 (-1.56%)

21:18
11/20/17
11/20
21:18
11/20/17
21:18
Upgrade
Superior Energy rating change  »

Superior Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

, LOW

Lowe's

$81.46

1.24 (1.55%)

20:25
11/20/17
11/20
20:25
11/20/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$78.90

-0.59 (-0.74%)

LOW

Lowe's

$81.46

1.24 (1.55%)

ADI

Analog Devices

$93.07

2.65 (2.93%)

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

HRL

Hormel Foods

$33.40

0.28 (0.85%)

CPB

Campbell Soup

$49.93

0.21 (0.42%)

BURL

Burlington Stores

$106.55

1.82 (1.74%)

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

DSW

DSW

$22.53

0.38 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CCLP

CSI Compressco

$5.28

-0.16 (-2.94%)

19:32
11/20/17
11/20
19:32
11/20/17
19:32
Hot Stocks
CSI Compressco names Owen Serjeant president »

CSI Compressco announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$57.62

1.13 (2.00%)

, AAPL

Apple

$169.98

-0.17 (-0.10%)

19:04
11/20/17
11/20
19:04
11/20/17
19:04
Periodicals
Applied Materials expected to purchase former Apple complex, Mercury News says »

An office complex that…

AMAT

Applied Materials

$57.62

1.13 (2.00%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

, FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

18:21
11/20/17
11/20
18:21
11/20/17
18:21
Periodicals
Fox reaches $90M settlement over sexual harassment scandal, Reuters says »

21st Century Fox reached…

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.00

2.87 (1.55%)

18:19
11/20/17
11/20
18:19
11/20/17
18:19
Hot Stocks
Muddy Waters says Alibaba numbers 'obviously fake' »

Short seller Muddy Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

, CHKP

Check Point

$102.98

0.83 (0.81%)

18:15
11/20/17
11/20
18:15
11/20/17
18:15
Recommendations
Palo Alto Networks, Check Point, Fortinet analyst commentary at JPMorgan »

Palo Alto quarter…

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

CHKP

Check Point

$102.98

0.83 (0.81%)

FTNT

Fortinet

$40.77

0.46 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 07

    Dec

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

18:14
11/20/17
11/20
18:14
11/20/17
18:14
Hot Stocks
Amazon announces cloud software for U.S spy agencies AWS Secret Region »

Amazon announced the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08
Recommendations
Deutsche cuts Bioverativ target to $53 after positive Roche data »

Deutsche Bank analyst…

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

CUBI

Customers Bancorp

$27.04

0.28 (1.05%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
Customers Bancorp: Flagship could raise capital in IPO transaction in 1H18 »

Customers Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
AT&T CEO says has offered DOJ solutions that were not accepted »

Says DOJ suit throws lots…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NGD

New Gold

$3.21

-0.02 (-0.62%)

18:02
11/20/17
11/20
18:02
11/20/17
18:02
Hot Stocks
New Gold announces sale of Peak Mines for $58M »

New Gold announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMI

Intermolecular

$1.31

0.1 (8.26%)

18:01
11/20/17
11/20
18:01
11/20/17
18:01
Hot Stocks
Intermolecular partners with SITRI to develop MtM technologies »

Intermolecular, Inc and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CMCSA

Comcast

$35.83

-0.33 (-0.91%)

18:00
11/20/17
11/20
18:00
11/20/17
18:00
Initiation
Comcast initiated at Buckingham »

Comcast initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

17:59
11/20/17
11/20
17:59
11/20/17
17:59
Hot Stocks
Mellanox up nearly 6% after Starboard discloses a 9.8% stake in the company »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

17:58
11/20/17
11/20
17:58
11/20/17
17:58
Initiation
Planet Fitness initiated at DA Davidson »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$44.43

0.86 (1.97%)

17:57
11/20/17
11/20
17:57
11/20/17
17:57
Downgrade
Teradyne rating change at Deutsche Bank »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CBS

CBS

$55.93

-0.81 (-1.43%)

17:56
11/20/17
11/20
17:56
11/20/17
17:56
Periodicals
CBS News suspends Charlie Rose following sexual harassment claims, AP says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$55.93

-0.81 (-1.43%)

17:55
11/20/17
11/20
17:55
11/20/17
17:55
Periodicals
Eight women accuse Charlie Rose of sexual harassment, Washington Post says »

Eight women have said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RELY

Real Industry

$0.52

0.1643 (45.92%)

17:38
11/20/17
11/20
17:38
11/20/17
17:38
Hot Stocks
Real Industry, Real Alloy receive court approval of 'first day' motions »

Real Industry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.